placebo + bortezomib + dexamethasone

This is a combination regimen consisting of a placebo, bortezomib, and dexamethasone. Bortezomib is a small molecule proteasome inhibitor that disrupts the 26S proteasome, leading to apoptosis in cancer cells. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressant properties; it induces apoptosis in certain hematologic malignancies. The inclusion of "placebo" indicates this regimen is used as a control arm in clinical trials rather than as an active therapeutic combination. This specific combination may be used to compare against other regimens (such as those including additional active agents) for diseases like multiple myeloma.

Other names

placebo plus bortezomib and dexamethasoneplacebo/bortezomib/dexamethasone